Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Adenocarcinoma × cabazitaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 51 Neoplasm Metastasis 11 Neoplasms 8 Recurrence 7 Prostate Cancer Metastatic 6 Breast Neoplasms 5 Carcinoma, Transitional Cell 4 Stomach Neoplasms 3 Neoplastic Cells, Circulating 3 Metastatic Castration-resistant Prostate Cancer 3 Brain Neoplasms 3 Urinary Bladder Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Prostatic Neoplasms, Castration-Resistant 2 Ovarian Neoplasms 2 Glioblastoma 2 Carcinoma, Squamous Cell 2 Carcinoma, Non-Small-Cell Lung 2 Thrombocytosis 1 Solid Cancer 1 Small Cell Lung Carcinoma 1 Prostate Cancer, Hereditary, 7 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Penile Neoplasms 1 Pancreatic Neoplasms 1 Oligodendroglioma 1 Nonseminomatous germ cell tumor 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1

Interventions

Oxaliplatin 42 Gemcitabine 41 Fluorouracil 37 pembrolizumab 29 Capecitabine 29 Leucovorin 26 Docetaxel 25 Cisplatin 24 Paclitaxel 21 Carboplatin 18 Bevacizumab 17 Irinotecan 16 130-nm albumin-bound paclitaxel 16 Radiotherapy 15 Pemetrexed 15 Nivolumab 13 Albumin-Bound Paclitaxel 13 Cyclophosphamide 10 Ramucirumab 9 zolbetuximab 7 Trastuzumab 7 Radiosurgery 7 Drug Therapy 7 trastuzumab deruxtecan 6 cemiplimab 6 Taxes 6 Erlotinib Hydrochloride 6 Blood Specimen Collection 6 durvalumab 5 Sorafenib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01952223 2025-07-30

PEACE2

UNICANCER

Phase 3 Active not recruiting

Adenocarcinoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡